Saturday 17 October 2026
Export MGTX’s income statement to Excel — free account
MeiraGTx Holdings PLC
MGTX Healthcare Biotechnology
MeiraGTx Holdings PLC’s revenue for fiscal 2025 (year ended December 2025) was $81.4 million, up 144.6% from fiscal 2024. In the quarter to June 2026, revenue grew 8,608.6%, EPS grew 466.7%, free cash flow grew 13.1% and total debt rose 28.6%, each against the same quarter a year earlier.
9.28
0.61
−6.17%
Follow MGTX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 17.78 |
P/S ratio |
24.30 | 7.86 | 8.83 | 3.11 | |
P/FCF ratio |
0.00 | 0.00 | 164.35 | 122.01 | |
P/Operating CF |
(54.54) | 13.71 | 39.53 | (32.05) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 5.72 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 5.73 | |
EV/Sales |
24.18 | 7.66 | 8.55 | 3.00 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 6.04 | |
EV/Operating CF |
(5.70) | (13.44) | 82.42 | 87.08 | |
EV/FCF |
(5.50) | (12.45) | 159.27 | 117.75 | |
Quick Ratio |
0.17 | 0.69 | 0.51 | 3.23 | |
Current Ratio |
0.22 | 0.75 | 0.55 | 3.76 | |
Net Debt/EBITDA |
0.08 | (0.54) | 0.58 | (0.17) | |
Debt/Assets |
6.09% | 20.37% | 20.35% | 25.25% | |
Debt/Equity |
(0.28) | (8.60) | (0.86) | 0.46 | |
Asset Turnover |
0.11 | 0.32 | 0.34 | 1.34 | |
Operating CF/Net income |
0.24 | 3.09 | (0.38) | (0.24) | |
Capex/Depreciation |
(0.16) | (0.20) | (0.61) | (0.10) | |
Interest Coverage |
(15.02) | 8.67 | (14.33) | 69.66 | |
Research and Development Expense of Revenue |
7,934.63% | 40.88% | 10,916.04% | 17.99% | |
Selling, General and Administrative Expense of Revenue |
3,320.98% | 23.36% | 3,047.10% | 3.74% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
1,451.95% | 7.43% | 1,247.10% | 1.18% | |
Graham Net Nets |
(0.29) | (0.25) | (0.29) | 0.03 | |
Graham Number |
4.88 | 1.52 | 4.88 | 6.35 | |
Earnings Yield |
(25.64%) | (17.86%) | (17.09%) | 5.63% | |
Free Cash Flow Yield |
(18.09%) | (7.83%) | 0.61% | 0.82% | |
Revenue per Share |
0.01 | 0.94 | 0.00 | 3.52 | |
Operating CF per Share |
(0.15) | 0.58 | 0.22 | (0.42) | |
Capex per Share |
(0.01) | (0.01) | (0.02) | 0.00 | |
Free Cash Flow per Share |
(0.16) | 0.57 | 0.19 | (0.43) | |
Cash per Share |
0.18 | 0.82 | 0.88 | 1.57 | |
Shareholders Equity per Share |
(0.50) | (0.07) | (0.71) | 2.36 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.50) | (0.07) | (0.71) | 2.36 | |
Free Cash Flow |
(12.76) | 45.95 | 15.80 | (38.87) | |
Working Capital |
(118.75) | (30.79) | (79.93) | 160.25 | |
Capital Expenditures |
(0.55) | (0.68) | (2.01) | (0.33) | |
Net Current Asset Value |
(195.85) | (158.46) | (206.58) | 37.68 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 6.48 | |
Capex to Sales |
1.33 | 0.01 | 6.85 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 6.71 | |
| Other line items | |||||
Average Receivables |
10.12 | 13.98 | 11.46 | 25.53 | |
Average Payables |
25.52 | 16.83 | 18.47 | 18.63 | |
Average Assets |
244.48 | 257.09 | 234.33 | 297.58 | |
Average Common Equity |
27.59 | 31.02 | (12.52) | 109.37 |
Columns are period end dates